GlassScriptPhysician profile
Barry J Brock
NPI 1427060011
$7,971.71
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2020: $262 · 2021: $1,118 · 2022: $4,520 · 2023: $718 · 2024: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,382.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $3,956.37 | 2019-2024 | |
| Abbvie INC. | $895.47 | 2019-2023 | Lo Loestrin Fe, Liletta |
| Viiv Healthcare Company | $394.45 | 2023-2024 | Dovato |
| Celularity INC. | $300.00 | 2021 | |
| Therapeuticsmd, INC. | $289.75 | 2019-2022 | |
| Exeltis, USA INC. | $243.68 | 2021-2024 | Slynd |
| Mayne Pharma Commercial LLC | $235.71 | 2021-2024 | |
| Agile Therapeutics, INC. | $147.06 | 2022-2024 | Twirla |
| Allergan, INC. | $146.98 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $137.96 | 2023-2024 | Myfembree |
| Scynexis, INC. | $123.91 | 2022 | |
| Shield Therapeutics INC | $116.95 | 2022-2023 | Accrufer |
| Myovant Sciences INC. | $114.80 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $85.67 | 2019-2021 | |
| Medicem INC. | $82.37 | 2020-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $80.62 | 2022-2023 | Acessa Provu System, Aptima |
| Baxter Healthcare | $75.34 | 2022-2023 | Perclot |
| Daiichi Sankyo INC. | $63.62 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.69 | 2019-2020 | |
| Coopersurgical, INC. | $51.34 | 2019-2022 | |
| Evofem Biosciences, INC. | $50.09 | 2021 | |
| Vertical Pharmaceuticals, LLC | $37.52 | 2019-2020 | |
| Lilly USA, LLC | $35.82 | 2021 | |
| Ascend Therapeutics US, LLC | $34.01 | 2021 | |
| Dysis Medical, INC. | $30.16 | 2020-2022 | |
| Becton, Dickinson and Company | $28.03 | 2024 | Bd Onclarity |
| Meditrina | $27.97 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.43 | 2022 | |
| Channel Medsystems, INC. | $22.50 | 2022-2023 | |
| Organon LLC | $19.68 | 2021 | |
| Aspira Women'S Health INC | $16.99 | 2021 | |
| Avion Pharmaceuticals | $15.20 | 2021 | |
| Novo Nordisk INC | $14.19 | 2019 | |
| Mission Pharmacal Company | $13.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Brock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.